• AgoraVox sur Twitter
  • RSS
  • Agoravox TV
  • Agoravox Mobile


Commentaire de njama

sur GARDASIL augmentation du taux de cancer du col chez les vaccinées confirmée sur analyse des registres officiels des cancers


Voir l'intégralité des commentaires de cet article

njama njama 5 octobre 2019 12:57

Page 10
« Historically, HPV testing [15] was introduced to compensate for the poor sensitivity and specificity of the Pap smear cytology often used as a diagnostic tool for borderline precancerous lesions. The only FDA approved Digene Hybrid Capture 2 (HC2) assay is commonly used to determine if a cervicovaginal lavage sample harbors »high-risk« HPVs [16], as an adjunctive test for evaluation of the cytologically borderline cases [17-19]. However, it is now recognized that persistent infection of a »high-risk« HPV, not the HPV virus itself, is the pivotal promoter incausing cervical precancerous lesions and cancer [7-10].
Most of HPV infections, even caused by »high-risk« genotypes, are transient with normal Pap cytology in sexually active young women [1, 3-6]. In 93% of the initially infected women, the same viral type is not detected upon re-examination four menstrual cycles later [20]. The median duration of positivity detectable by PCR for a specific HPV type in these young women is 168 days [21]. Multiple »high-risk« HPV infections do not constitute a higher risk for the development of cervical neoplasia when compared with single high-risk HPV infection [22]. For the development and maintenance of a high-grade squamous intra epithelial lesion (SIL), the risk is greatest in women positive for the same genotype of HPV on repeated testing [7-9]. Viral load is not a useful parameter to predict high-grade SIL [23]. High-grade SIL is often associated with a viral DNA load lower than that observed in less severely affected cells [24] »

Répondre Signaler un abus

Voir ce commentaire dans son contexte


Derniers commentaires




Palmarès